Ryan Daws
Equibles does not estimate personal net worth.
Get an email with a short summary when enGene Therapeutics Inc. publishes a filing, an earnings call transcript or a press release.
Get ENGN alertsAbout Ryan Daws
Ryan Daws is recorded as CFO at enGene Therapeutics Inc. (ENGN) since November 27, 2023. enGene Therapeutics Inc. reported in an 8-K filed June 15, 2026 that Ryan Daws resigned as Chief Financial Officer, effective July 15, 2026. enGene Therapeutics Inc. reported in an 8-K filed November 29, 2023 that Ryan Daws was appointed Chief Financial Officer and Head of Business Development, effective November 29, 2023. enGene Therapeutics Inc. reported in an 8-K filed November 29, 2023 that Ryan Daws was appointed Chief Financial Officer and Head of Business Development, effective November 27, 2023. The proxy statement of enGene Therapeutics Inc. reports total compensation of $2,216,126 for Ryan Daws in fiscal 2025, including a base salary of $473,000. enGene Therapeutics Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at enGene Therapeutics Inc. includes Ron Cooper (CEO and Board Member), Ronald H. W. Cooper (CEO and Board Member), Ronald H.W. Cooper (CEO and Board Member) and 7 others.
“on June 15, 2026, the Company announced that its Chief Financial Officer, Ryan Daws, will depart the Company effective July 15, 2026 (the "Daws Separation Date").”
“enGene Holdings Inc. (“enGene,” Nasdaq: ENGN, ENGNW), a clinical-stage genetic medicines company whose lead program is in a pivotal study for BCG-unresponsive non-muscle invasive bladder cancer (NMIBC), today announced the appointment of Ryan Daws as Chief Financial Officer and Head of Business Development.”
Affiliation history
-
Current
2023-11-27–present
-
Start not stated–2026-07-15
Company network
Leadership on record at enGene Therapeutics Inc.
- Ron Cooper CEO, Board Member
- Ronald H. W. Cooper CEO, Board Member
- Ronald H.W. Cooper CEO, Board Member
- Alex Nichols COO
- Alexander Nichols COO
- Dr. Alex Nichols COO
- Anthony Cheung CTO
- Joan Connolly CTO
- Dr. William Grossman Board Member
- Gerald Brunk Board Member
Executive compensation
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | enGene Therapeutics Inc. (ENGN) | Chief Financial Officer | $473,000 | $2,216,126 |